UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000060180
Receipt number R000068731
Scientific Title Collection of Pharyngeal Images and AI Development for Patients with Seasonal Influenza or COVID-19(images-2025-1)
Date of disclosure of the study information 2025/12/23
Last modified on 2025/12/23 13:59:27

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Collection of Pharyngeal Images and AI Development for Patients with Seasonal Influenza or COVID-19(images-2025-1)

Acronym

AI Development and Pharyngeal Image Collection for Influenza or COVID-19

Scientific Title

Collection of Pharyngeal Images and AI Development for Patients with Seasonal Influenza or COVID-19(images-2025-1)

Scientific Title:Acronym

AI Development and Pharyngeal Image Collection for Influenza or COVID-19

Region

Japan


Condition

Condition

Seasonal influenza
COVID-19

Classification by specialty

Medicine in general Infectious disease Chest surgery
Pediatrics Oto-rhino-laryngology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To create a dataset by collecting pharyngeal images and clinical information from patients suspected of having influenza or COVID-19 infection, and to conduct development, including performance improvement, of medical devices utilizing artificial intelligence that aid in the diagnosis of influenza, COVID-19, and other diseases.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Not applicable

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

4 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Persons who have undergone antigen qualitative testing for influenza and novel coronavirus with suspected influenza or COVID-19.
2) Persons aged 6 years or older at the time consent is obtained (however, persons 4 years of age or older may be accepted at pediatric clinics that have received the necessary explanation from Iris Corporation).
3) Persons who have obtained the free written consent of the individual or a surrogate to participate in this study
4) Persons who fall under one or more of the following items from (1) to (4) (however, for items (1) to (3), only persons within 48 hours of the onset of symptoms are counted under the relevant item)
(i) Fever of 37.0 C or more (including cases where the temperature exceeded 37 C measured at home, etc.)
(ii) With systemic symptoms such as arthralgia, myalgia, headache, or general malaise, anorexia, etc.
(iii) Respiratory symptoms with cough, sore throat or nasal discharge/nasal obstruction
(iv) Suspected of having influenza or COVID-19 according to a doctor's judgement, such as through concentrated contact with a patient who has influenza or COVID-19

Key exclusion criteria

1) Persons with impaired consciousness or breathing disorders (respiratory failure)
2) Persons with moderate or severe gingival or dental disease or upset teeth that may be aggravated by the use of the research equipment
3) Persons with trauma or damage to the maxillofacial, dental, oral or pharyngeal regions that may be aggravated by the use of the research equipment, or who have undergone surgery on these parts within one month
4) Persons who repeatedly vomit.
5) Persons who have difficulty in taking pictures in a sitting position.
6) Persons who are receiving house calls.
7) Other persons who are judged by the principal investigator or research assistant to be unsuitable as subjects for the study

Target sample size

11000


Research contact person

Name of lead principal investigator

1st name Memori
Middle name
Last name Fukuda

Organization

Aillis,Inc.

Division name

Clinical Research Promotion Office

Zip code

101-0042

Address

4-28, Kanda-Higashimatsushitacho, Chiyoda-ku, Tokyo

TEL

03-5218-2374

Email

clinicalresearch-promotion@aillis.jp


Public contact

Name of contact person

1st name Memori
Middle name
Last name Fukuda

Organization

Aillis,Inc.

Division name

Clinical Research Promotion Office

Zip code

101-0042

Address

4-28, Kanda-Higashimatsushitacho, Chiyoda-ku, Tokyo

TEL

03-5218-2374

Homepage URL


Email

clinicalresearch-promotion@aillis.jp


Sponsor or person

Institute

Aillis,Inc.

Institute

Department

Personal name



Funding Source

Organization

Aillis,Inc.

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Aillis,Inc. Research Ethics Review Board

Address

4-28, Kanda-Higashimatsushitacho, Chiyoda-ku, Tokyo 101-0042, Japan

Tel

03-5218-2374

Email

aillis-irb@aillis.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2025 Year 12 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2025 Year 11 Month 07 Day

Date of IRB

2025 Year 11 Month 17 Day

Anticipated trial start date

2025 Year 12 Month 03 Day

Last follow-up date

2026 Year 04 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Research on Pharyngeal Image Collection and AI Development


Management information

Registered date

2025 Year 12 Month 23 Day

Last modified on

2025 Year 12 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068731